Eltrombopag Tablets + Eltrombopag PfOS

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopenic, Idiopathic

Conditions

Purpura, Thrombocytopenic, Idiopathic

Trial Timeline

Jun 18, 2013 โ†’ Jul 4, 2017

About Eltrombopag Tablets + Eltrombopag PfOS

Eltrombopag Tablets + Eltrombopag PfOS is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT02201290. Target conditions include Purpura, Thrombocytopenic, Idiopathic.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02201290Phase 3Completed